MedTech M&A Report Q3 2024

Strategic perspectives on the M&A landscape of the MedTech industry

Further increase in domestic M&A activities

In our latest MedTech M&A Report Q3 2024, we highlight the M&A trends in the MedTech sector at both global and Swiss level.

Multiples remain high and are above the long-term median, which makes the market attractive for sellers. Strategists are again increasingly acting as buyers of MedTech companies and are primarily coming from America, followed by Europe. Cross-border transactions are therefore a decisive element in the MedTech M&A market.

Please do not hesitate to contact our experts, who will be happy to discuss further points of interest or questions on the topic with you and show you how Oaklins can add value with its close international network of contacts. We are at your disposal to discuss your specific M&A and corporate finance needs.

Your contact persons

Oaklins d.zuerrer 829 weiss
David Zürrer Basel, Switzerland
Partner
View profile
Oaklins r.tracia 406 weiss
Dr. Roberto Tracia Bern, Switzerland
Partner
View profile

Completed M&A transactions in the healthcare sector

About Oaklins

United by a strong belief that we can achieve the extraordinary. Oaklins is a global team of 800+ financial advisory professionals in 40 countries providing M&A, growth equity, ECM, debt advisory and corporate finance services to support entrepreneurs, corporates and investors in reaching their goals.

Related Healthcare articles